KMT2C/D deficiency promotes breast cancer metastasis by regulating KDM6A-mediated epigenetic remodeling

Zhao Huang; Wei Zhao

doi:10.1002/mog2.95

MEDCOMM - Oncology ›› 2024, Vol. 3 ›› Issue (4) : e95 DOI: 10.1002/mog2.95

HIGHLIGHT

KMT2C/D deficiency promotes breast cancer metastasis by regulating KDM6A-mediated epigenetic remodeling

Zhao Huang ¹^,^†
, Wei Zhao ²

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhao Huang, Wei Zhao. KMT2C/D deficiency promotes breast cancer metastasis by regulating KDM6A-mediated epigenetic remodeling. MEDCOMM - Oncology, 2024, 3(4): e95 DOI:10.1002/mog2.95

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	SeehawerM, LiZ, NishidaJ, et al. Loss of KMT2C or KMT2D drives brain metastasis via KDM6A-dependent upregulation of MMP3. Nature Cell Biol. 2024;26(7):1165-1175.

[2]	BianchiniG, De Angelis C, LicataL, GianniL. Treatment landscape of triple-negative breast cancer-expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91-113.

[3]	JiangZ, OuyangQ, SunT, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30(1):249-256.

[4]	DorighiKM, SwigutT, HenriquesT, et al. Mll3 and Mll4 facilitate enhancer RNA synthesis and transcription from promoters independently of H3K4 monomethylation. Mol Cell. 2017;66(4):568-576.e4.

[5]	LangilleE, Al-Zahrani KN, MaZ, et al. Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis, and promotes breast cancer. Cancer Discov. 2022;12(12):2930-2953.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).